Table. Comparison of Current Systemic Therapy Options in Adjuvant and Metastatic Settings of Colon, Breast, and Non–Small Cell Lung Cancers.
| Cancer type | Agents for metastatic disease, No. | Agents for adjuvant use, No. | Metastatic agents also used for adjuvant treatment, No./total No. (%) | Delay in use between metastatic and adjuvant setting, mean (SD), y | Agents, No./Total No. (%) | ||
|---|---|---|---|---|---|---|---|
| Metastatic agents supported by positive trial | Adjuvant agents supported by positive trial | Metastatic-only agents assessed for adjuvant use | |||||
| Non–small cell lung cancer | 24 | 7 | 7/24 (29.2) | 12.0 (4.9) | 12/24 (50.0) | 6/7 (85.7) | 10/17 (58.8) |
| Breast | 30 | 15 | 14/30 (46.7) | 8.3 (6.2) | 17/30 (56.7) | 14/15 (93.3) | 14/16 (87.5) |
| Estrogen receptor and progesterone receptor positive | 26 | 11 | 10/26 (38.5) | 9.1 (7.0) | 13/26 (50.0) | 11/11 (100.0) | 14/16 (87.5) |
| ERBB2 positive | 15 | 9 | 8/15 (53.3) | 8.3 (5.9) | 10/15 (66.7) | 8/9 (88.9) | 6/6 (100.0) |
| Triple-negative breast cancer | 11 | 4 | 4/11 (36.4) | 10.2 (6.9) | 6/11 (54.5) | 4/4 (100.0) | 5/5 (100.0) |
| Colon | 15 | 3 | 3/15 (20.0) | 12.8 (4.2) | 10/15 (66.7) | 3/3 (100.0) | 7/12 (58.3) |
| All cancers | 69 | 25 | 24/69 (34.8) | 10.0 (7.5) | 39/69 (56.5) | 23/25 (92.0) | 31/45 (68.9) |